Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Yvonne Nestoriuc, Franziska Schuricht, Ute-Susann Albert, Winfried Rief, Pia von Blanckenburg
Publikováno v:
BMC Cancer
Background Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients’ quality of life and cause non-ad
Autor:
Michael Baumann, Arnoud J. Templeton, Beat Thürlimann, Thomas Ruhstaller, Sarah Stoll, Madeleine Schwizer, Michael Mark, Daniel Dietrich
Publikováno v:
BMC Cancer
Background Besides conventional adjuvant therapies, many breast cancer survivors engage in various activities like exercise, diet and complementary and alternative medicine (CAM) in order to improve their prognosis. Little is known about specific int
Autor:
Jeffrey Peppercorn, Lee W. Jones, Brant A. Inman, Pamela S. Douglas, James E. Herndon, P. Kelly Marcom, Jason D. Allen, Neil D. Eves, William E. Kraus
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 531 (2010)
BMC Cancer, Vol 10, Iss 1, p 531 (2010)
Background The Exercise Intensity Trial (EXcITe) is a randomized trial to compare the efficacy of supervised moderate-intensity aerobic training to moderate to high-intensity aerobic training, relative to attention control, on aerobic capacity, physi
Autor:
Sandro Anchisi, Richard Cathomas, Markus Borner, A. Müller, Roger von Moos, Daniela Bärtschi, Jürg Bernhard, Marcus Vetter, Thomas Ruhstaller, Daniel Rauch, Kyung-Jae Na, Martin Bigler, Ralph Winterhalder, Andreas Wicki, Khalil Zaman, U Hasler-Strub, Andreas Trojan, Klazien Matter-Walstra, Marc Küng, Tamara Rordorf, Christoph Rochlitz
Publikováno v:
BMC Cancer
Bmc Cancer, vol. 16, no. 1, pp. 780
Bmc Cancer, vol. 16, no. 1, pp. 780
Background Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/
Publikováno v:
BMC Cancer
Background People with cancer receive regular structured follow up after initial treatment, usually by a specialist in a cancer centre. Increasing numbers of cancer survivors prompts interest in alternative structured follow-up models. There is world
Autor:
Edith Pituskin, Margaret L. McNeely, John R. Mackey, Mark J. Haykowsky, Ian Paterson, Neil Chua
Publikováno v:
BMC Cancer
Cancer is the leading cause of premature death in Canada. In the last decade, important gains in cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also result in cardiovascular "toxicity". Furthe
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 33 (2012)
BMC Cancer
BMC Cancer
Background Increased health care costs have made it incumbent on health-care facilities and physicians to demonstrate both clinical and cost efficacy when recommending treatments. Though studies have examined the cost-effectiveness of adjuvant gosere
Publikováno v:
BMC Cancer
Loss of lean body mass (LBM) is a common occurrence after treatment for breast cancer and is related to deleterious metabolic health outcomes [Clin Oncol, 22(4):281–288, 2010; Appl Physiol Nutr Metab, 34(5):950–956, 2009]. The aim of this researc
Autor:
Kraus-Tiefenbacher Uta, Keller Anke, Welzel Grit, Christian Neumaier, Gerhardt Axel, Wenz Frederik, Sütterlin Marc, Sperk Elena, Abo-Madyan Yasser
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 171 (2012)
BMC Cancer
BMC Cancer
Background Patients ≥ 70 years with small, low-risk breast cancer who are operated but not irradiated how local relapse rates around 4% after 4 years. With adjuvant whole breast radiotherapy (WBRT) the local relapse rate drops to 1% after 4 years u